Related references
Note: Only part of the references are listed.Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection
Hironori Kobayashi et al.
ANNALS OF SURGERY (2012)
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
I. Borbath et al.
EUROPEAN JOURNAL OF CANCER (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
D. Santini et al.
CURRENT CANCER DRUG TARGETS (2011)
Deoxycitidine Kinase Is Associated With Prolonged Survival After Adjuvant Gemcitabine for Resected Pancreatic Adenocarcinoma
Raphael Marechal et al.
CANCER (2010)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
H. Akita et al.
ONCOGENE (2009)
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
F. Eckel et al.
BRITISH JOURNAL OF CANCER (2007)
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Shin Nakahira et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
